Telo Genomics Launches Multiple Myeloma Advisory Board at the American Society of Hematology Annual Meeting
Toronto, Ontario--(Newsfile Corp. - February 22, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is excited to announce the launch of our inaugural multiple myeloma clinical advisory board ("MM CAB"). The advisory group met at the American Society of Hematology ("ASH") meeting in New Orleans on December 13, 2022. This internationally recognized group of clinical advisors provided feedback and advice to the Telo management team in advance of the company's...
2023-02-22 8:30 AM EST
Telo Genomics Appoints Kris Weinberg as Chief Executive Officer
Toronto, Ontario--(Newsfile Corp. - December 12, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce the appointment of Kris Weinberg as Chief Executive Officer ("CEO"), effective today. Telo Genomics' current CEO, Sherif Louis PhD, will assume the position of President & Chief Technology Officer. "These executive changes are integral to TELO's long term growth strategy," said John Meekison, Telo Genomics Board Director & Chair of the Audit...
2022-12-12 8:45 AM EST
Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual Meeting
Toronto, Ontario--(Newsfile Corp. - December 8, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce the formation of a multiple myeloma advisory board ("MM Advisory Board"). Driven by the success of TELO's recent clinical studies, announced on September 14, 2022, and as part of the Company's commercialization strategy, the Company has prioritized the formation of an internationally recognized clinical advisory board to help guide the...
2022-12-08 8:30 AM EST
Telo Genomics Launches a Minimal Residual Disease Clinical Trial in Multiple Myeloma
Toronto, Ontario--(Newsfile Corp. - November 9, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce today that it is launching a clinical trial to monitor multiple myeloma disease progression in post-treated patients, by measuring and profiling the minimal residual disease ("MRD") in these patients. The clinical trial is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada. The trial is...
2022-11-09 8:30 AM EST
Telo Genomics Engages Key Opinion Leader to Form and Chair Myeloma Advisory Board
Toronto, Ontario--(Newsfile Corp. - October 18, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has recently engaged Richard A. Bender MD, FACP, a veteran multiple myeloma ("MM") clinician, key opinion leader and medical diagnostics expert to establish and chair TELO's MM clinical advisory board (the "Advisory Board"). Driven by the progress of TELO's clinical studies announced on September 14, 2022, and as part of the Company's...
2022-10-18 8:30 AM EDT
Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study
Toronto, Ontario--(Newsfile Corp. - September 14, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that the initial clinical validation stage of its ongoing clinical study for smoldering multiple myeloma ("SMM"), in collaboration with the Mayo Clinic, has completed review and analysis of its first cohort, consisting of 187 patients and has exceeded its targeted endpoints. In July 2022, the Company announced that it had completed...
2022-09-14 8:45 AM EDT
Telo Genomics Completes Processing of Multiple Myeloma Drug Resistance Patient Samples
Toronto, Ontario--(Newsfile Corp. - August 17, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces the completion of the laboratory processing and analysis of patient samples related to its multiple myeloma drug resistance clinical study. The patient samples were provided by the Mayo Clinic as part of an ongoing collaboration to evaluate the Company's prognostic technology for multiple myeloma ("MM"). TELO's study results have now been submitted back to...
2022-08-17 8:45 AM EDT
Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma
Toronto, Ontario--(Newsfile Corp. - July 13, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has commenced the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma ("MM") patients that are at high-risk of developing treatment resistance. This study is the second study being carried out in collaboration with the Mayo Clinic to evaluate the Company's prognostic technology to address...
2022-07-13 8:45 AM EDT
Telo Genomics Completes Processing and Analysis of Smoldering Multiple Myeloma Patient Samples
Toronto, Ontario--(Newsfile Corp. - July 6, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces the completion of the laboratory processing and analysis component of its clinical study for TELO's lead prognostic test for smoldering multiple myeloma ("SMM"). The SMM patient samples were provided by the Mayo Clinic in Q1 2022 as part of an ongoing collaboration to evaluate the Company's prognostic technology for multiple myeloma ("MM"). TELO's study...
2022-07-06 8:15 AM EDT
Telo Genomics Announces Successful Validation of Its Proprietary Automation Tools for Smoldering Multiple Myeloma
Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces that it has completed the validation of a suite of proprietary automation tools developed using cutting-edge machine learning, deep machine learning and artificial intelligence technologies to maximize the efficiency and throughput of its technology workflow. The validation was conducted on a subset of smoldering multiple myeloma (SMM) patient samples that...
2022-05-31 8:45 AM EDT
Telo Genomics Announces Investor Relations Agreement and Option Grants
Toronto, Ontario--(Newsfile Corp. - March 15, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has engaged Tracey Kidd ("Kidd") to perform services related to investor relations activities for the Company, as defined in accordance with the polices of the TSX Venture Exchange ("TSXV") and applicable securities laws. Pursuant to an engagement agreement entered into with Kidd on March 15, 2022 (the "Engagement Agreement"), Kidd will...
2022-03-15 8:45 AM EDT
Telo Genomics Launches Clinical Validation of its Smoldering Multiple Myeloma Diagnostic Test
Toronto, Ontario--(Newsfile Corp. - March 7, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) (the "Company" or "TELO") announces that it has received clinical samples from its collaborator, Mayo Clinic, to conduct the clinical validation of the Company's lead product in development, its TeloView® prognostic test for segregating high risk and low risk smoldering multiple myeloma (SMM) patients. TELO announced on March 28, 2021, that it had completed the feasibility stage of...
2022-03-07 8:45 AM EST
Telo Genomics Appoints Dr. McGlennen as Board Director, a Leader in Commercializing Novel Diagnostic Technologies
Toronto, Ontario--(Newsfile Corp. - February 3, 2022) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that Dr. Ron McGlennen, President and Founder of the medical laboratory Access Genetics, Minnesota, USA, has joined its Board of Directors. Dr. McGlennen brings unique and valuable expertise to TELO's board with extensive experience in successfully introducing novel diagnostics technologies into clinical laboratories across the USA. Dr. McGlennen brings...
2022-02-03 8:51 AM EST
Telo Genomics Advances Its Lead Product and Implements Automation to Its Workflow
Toronto, Ontario--(Newsfile Corp. - January 19, 2022) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") announces the launch of a validation study to accelerate the commercialization of its lead product in development for smoldering multiple myeloma (SMM) patients. The Company also announces that it has recently implemented in its workflow several proprietary automation solutions that employed cutting edge machine learning and artificial intelligence algorithms. TELO has recently...
2022-01-19 8:55 AM EST
Telo Genomics Announces OTCQB Venture Market Listing
Toronto, Ontario--(Newsfile Corp. - December 7, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the "OTCQB"). TELO commenced trading on the OTCQB at market open on December 06, 2021 under the symbol "TDSGF". TELO common shares will continue to trade on the Toronto Venture Exchange under the symbol TELO. The OTCQB Venture Market, operated by OTC Markets Group Inc., is...
2021-12-07 1:24 PM EST
Telo Genomics Announces the Outcome of its Participation in the International Myeloma Workshop and Clinical Studies Progress
Toronto, Ontario--(Newsfile Corp. - October 13, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce updates related to its recent participation in the International Multiple Myeloma Workshop in Vienna, Austria, and progress of the ongoing clinical studies in collaboration with the Mayo Clinic. TELO has recently participated in the International Myeloma Workshop (IMW 2021) that took place in Vienna, Austria. During the IMW 2021 TELO held important meetings...
2021-10-13 8:30 AM EDT
Telo Genomics Adopts Advanced Notice Provisions in By-Laws
Toronto, Ontario--(Newsfile Corp. - October 5, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announces its board of directors (the "Board") has adopted amendments to its By-Laws (the "Amended By-Laws") to include advance notice provisions (the "Advance Notice Provisions") which require shareholders of the Company ("Shareholders") to provide advance notice to the Company when nominating persons for election to the Board. The Advance Notice Provisions provide...
2021-10-05 8:30 AM EDT
Telo Genomics Announces Full-Services Investor Relations Agreement with Adelaide Capital
Toronto, Ontario--(Newsfile Corp. - September 21, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it has entered into a consulting agreement (the "Consulting Agreement") with Adelaide Capital Markets Inc. ("Adelaide") to provide investor relations consulting services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange (the "TSXV") and applicable legislation. Adelaide will provide investor relations and...
2021-09-21 8:45 AM EDT
Telo Genomics Participates in the 18th International Myeloma Society Workshop 2021
Toronto, Ontario--(Newsfile Corp. - September 9, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it is participating in the 18th International Myeloma Society Workshop 2021 (IMW 2021) taking place in Vienna, Austria between September 8th - 11th. Telo Genomics will showcase the clinical utility and unique advantages of its TeloView® technology, and its potential as a transformative liquid biopsy prognostics solution for managing multiple myeloma....
2021-09-09 8:30 AM EDT
Telo Genomics Engages Clinical and Regulatory Affairs Veteran to Lead the Company's ISO 15189 Certification & CLIA Laboratory Accreditation Undertaking
Toronto, Ontario--(Newsfile Corp. - August 9, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that the Company has entered into an agreement with the clinical laboratory veteran Mark Stene, Founder & President of MyClinLab® LLC, Austin, Texas USA. Mark Stene is a former senior executive with several clinical laboratories and medical device enterprises in the USA. Dr. Stene brings a record of accomplishment in guiding biotech companies through the...
2021-08-09 8:30 AM EDT